The permeability of puerarin loaded poly(butylcyanoacrylate) nanoparticles coated with polysorbate 80 on the blood-brain barrier and its protective effect against cerebral ischemia/reperfusion injury

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 8, 2013, Pages 1263-1270

  Zhao, Li Xia ^a,b   Liu, An Chang ^b   Yu, Shu Wen ^c   Wang, Zeng Xin ^d   Lin, Xiao Qian ^a   Zhai, Guang Xi ^a   Zhang, Qing Zhu ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^d Jinan Welcom Biochemical Pharmaceutical Company   (China)

Author keywords

Brain biodistribution; Nanoparticle; Neuroprotective effect; Poly(butylcyanoacrylate); Puerarin

Indexed keywords

NANOPARTICLE; POLY(BUTYLCYANOACRYLATE); POLYSORBATE 80; PUERARIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BODY WEIGHT; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG STRUCTURE; IN VITRO STUDY; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; RAT; REPERFUSION; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; TREATMENT RESPONSE; WATER CONTENT; ZETA POTENTIAL;

EID: 84883163735     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00769     Document Type: Article

References (49)

1. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int. J. Pharm., 298, 274-292 (2005).
2. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y. Heart disease and stroke statistics - 2009 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation, 119, 480-486 (2009).
3. Feher A, Pusch G, Koltai K, Tibold A, Gasztonyi B, Szapary L, Feher G. Statintherapy in the primary and the secondary prevention of ischaemic cerebrovascular diseases. Int. J. Cardiol., 148, 131-138 (2011).
4. Iguchi Y, Kimura K, Sone K, Miura H, Endo H, Yamagata S, Koide H, Suzuki K, Kimura T, Sakurai M, Mishima N, Yoshii K, Fujisawa H, Ebisutani S. Stroke incidence and usage rate of thrombolysis in a Japanese urban city: The Kurashiki stroke registry. J. Stroke Cerebrovasc. Dis., 22, 349-357 (2013).
5. Zhang ZG, Zhang QZ, Cheng YN, Ji SL, Du GH. Antagonistic effects of ultra-low-molecular-weight heparin against cerebral ischemia/reperfusion injury in rats. Pharmacol. Res., 56, 350-355 (2007).
6. Kay R, Woo J, Kreel L, Wong HY, Teoh R, Nicholls MG. Stroke subtypes among Chinese living in Hong Kong: the Shatin Stroke Registry. Neurology, 42, 985-987 (1992).
7. Nair SB, Dileep A, Rajanikant GK. Nanotechnology based diagnostic and therapeutic strategies for neuroscience with special emphasis on ischemic stroke. Curr. Med. Chem., 19, 744-756 (2012).
8. Yeung DK, Leung SW, Xu YC, Vanhoutte PM, Man RY. Puerarin, an isoflavonoid derived from Radix puerariae, potentiates endothelium-independent relaxation via the cyclic AMP pathway in porcine coronary artery. Eur. J. Pharmacol., 552, 105-111 (2006).
9. Gao L, Ji X, Song J, Liu P, Yan F, Gong W, Dang S, Luo Y. Puerarin protects against ischemic brain injury in a rat model of transient focal ischemia. Neurol. Res., 31, 402-406 (2009).
10. Zhang W, Liu CQ, Wang PW, Sun SY, Su WJ, Zhang HJ, Li XJ, Yang SY. Puerarin improves insulin resistance and modulates adipokine expression in rats fed a high-fat diet. Eur. J. Pharmacol., 649, 398-402 (2010).
11. Chen WC, Hayakawa S, Yamamoto T, Su HC, Liu IM, Cheng JT. Mediation of beta-endorphin by the isoflavone puerarin to lower plasma glucose in streptozotocin-induced diabetic rats. Planta Med., 70, 113-116 (2004).
12. Xu X, Zhang S, Zhang L, Yan W, Zheng X. The neuroprotection of puerarin against cerebral ischemia is associated with the prevention of apoptosis in rats. Planta Med., 71, 585-591 (2005).
13. 2-terminal kinase pathway in the neuroprotective effect of puerarin against 1-methyl-4-phenylpyridinium (MPP+)-induced apoptosis in PC-12 cells. Neurosci. Lett., 487, 88-93 (2011).
14. Chang Y, Hsieh CY, Peng ZA, Yen TL, Hsiao G, Chou DS, Chen CM, Sheu Jr. Neuroprotective mechanisms of puerarin in middle cerebral artery occlusion-induced brain infarction in rats. J. Biomed. Sci., 16, 9 (2009).
15. Prasain JK, Jones K, Brissie N, Moore R, Wyss JM, Barnes S. Identification of puerarin and its metabolites in rats by liquid chromatography-tandem mass spectrometry. J. Agric. Food Chem., 52, 3708-3712 (2004).
16. Shengmiao C, Chunshun Z, Zhonggui H. Uptaking characteristics of puerarin in Caco-2 model system. Chin. Tradit. Herbal Drugs, 38, 836-839 (2007).
17. Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm., 70, 75-84 (2008).
18. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev. Ind. Pharm., 28, 1-13 (2002).
19. Wang CX, Huang LS, Hou LB, Jiang L, Yan ZT, Wang YL, Chen ZL. Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model. Brain Res., 1261, 91-99 (2009).
20. Sun M, Gao Y, Guo CY, Cao FL, Song ZM, Xi YW, Yu AH, Li AG, Zhai GX. Enhancement of transport of curcumin to brain in mice by poly(n- butylcyanoacrylate) nanoparticle. J. Nanopart. Res., 12, 3111-3122 (2010).
21. Zhao LX, Liu AC, Sun M, Gu JS, Wang HG, Wang S, Zhang J, Guo CY, Duan R, Zhai GX. Enhancement of oral bioavailability of puerarin by polybutylcyanoacrylate nanoparticles. J. Nanomater., 2011, 8 (2011).
22. Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res., 1200, 159-168 (2008).
23. Bayat A, Larijani B, Ahmadian S, Junginger HE, Rafiee-Tehrani M. Preparation and characterization of insulin nanoparticles using chitosan and its quaternized derivatives. Nanomedicine, 4, 115-120 (2008).
24. Yan B, Xing D, Ding Y, Tao J, Du LJ. HPLC method for the determination and pharmacokinetic studies on puerarin in cerebral ischemia reperfusion rat plasma after intravenous administration of puerariae radix isoflavone. J. Pharm. Biomed. Anal., 37, 297-301 (2005).
25. Yan B, Wang W, Zhang L, Xing D, Wang D, Du L. Determination of puerarin in rat cortex by high-performance liquid chromatography after intravenous administration of Puerariae flavonoids. Biomed. Chromatogr., 20, 180-184 (2006).
26. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke, 20, 84-91 (1989).
27. Gao K, Jiang X. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int. J. Pharm., 310, 213-219 (2006).
28. Chaudhari KR, Ukawala M, Manjappa AS, Kumar A, Mundada PK, Mishra AK, Mathur R, Mönkkönen J, Murthy RS. Opsonization, biodistribution, cellular uptake and apoptosis study of PEGylated PBCA nanoparticle as potential drug delivery carrier. Pharm. Res., 29, 53-68 (2012).
29. Sun M, Zhao L, Guo C, Cao F, Chen H, Zhao L, Tan Q, Zhu X, Zhu F, Ding T, Zhai Y, Zhai G. Evaluation of an oral carrier system in rats: bioavailability and gastrointestinal absorption properties of curcumin encapsulated PBCA nanoparticles. J. Nanopart. Res., 14, 705-717 (2012).
30. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr. Opin. Solid St. M., 6, 319-327 (2002).
31. Feng SS, Huang GF. Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J. Control. Release, 71, 53-69 (2001).
32. Ren F, Chen RD, Wang Y, Sun YB, Jiang YD, Li GF. Paclitaxel-loaded poly(n-butylcyanoacrylate) nanoparticle delivery system to overcome multidrug resistance in ovarian cancer. Pharm. Res., 28, 897-906 (2011).
33. Reddy LH, Murthy RR. Influence of polymerization technique and experimental variables on the particle properties and release kinetics of methotrexate from poly(butylcyanoacrylate) nanoparticles. Acta Pharm., 54, 103-118 (2004).
34. Li Y, Pan WS, Chen SL, Xu HX, Yang DJ, Chan AS. Pharmacokinetic, tissue distribution, and excretion of puerarin and puerarin-phospholipid complex in rats. Drug Dev. Ind. Pharm., 32, 413-422 (2006).
35. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res., 16, 1564-1569 (1999).
36. Tr O, Ster SD, Ller U, Kreuter J. Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants. Int. J. Pharm., 61, 85-100 (1990).
37. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res., 674, 171-174 (1995).
38. Pan HP, Li G. Protecting mechanism of puerarin on the brain neurocyte of rat in acute local ischemia brain injury and local cerebral ischemia-reperfusion injury. Yakugaku Zasshi, 128, 1689-1698 (2008).
39. Xu L, Fagan SC, Waller JL, Edwards D, Borlongan CV, Zheng J, Hill WD, Feuerstein G, Hess DC. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusionreperfusion in rats. BMC Neurol., 4, 7 (2004).
40. Rogers DC, Campbell CA, Stretton JL, Mackay KB. Correlation between motor impairment and infarct volume after permanent and transient middle cerebral artery occlusion in the rat. Stroke, 28, 2060-2065, discussion, 2066 (1997).
41. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target., 10, 317-325 (2002).
42. Weiss CK, Kohnle MV, Landfester K, Hauk T, Fischer D, Schmitz-Wienke J, Mailänder V. The first step into the brain: uptake of NIO-PBCA nanoparticles by endothelial cells in vitro and in vivo, and direct evidence for their blood-brain barrier permeation. ChemMedChem, 3, 1395-1403 (2008).
43. Alyaudtin RN, Reichel A, Löbenberg R, Ramge P, Kreuter J, Begley DJ. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J. Drug Target., 9, 209-221 (2001).
44. Ramge P, Unger RE, Oltrogge JB, Zenker D, Begley D, Kreuter J, Von Briesen H. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Eur. J. Neurosci., 12, 1931-1940 (2000).
45. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target., 10, 317-325 (2002).
46. Nerurkar MM, Burton PS, Borchardt RT. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res., 13, 528-534 (1996).
47. Terasaki T, Hosoya K. The blood-brain barrier efflux transporters as a detoxifying system for the brain. Adv. Drug Deliv. Rev., 36, 195-209 (1999).
48. Spudich A, Kilic E, Xing H, Kilic U, Rentsch KM, Wunderli-Allenspach H, Bassetti CL, Hermann DM. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat. Neurosci., 9, 487-488 (2006).
49. Nerurkar MM, Ho NF, Burton PS, Vidmar TJ, Borchardt RT. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J. Pharm. Sci., 86, 813-821 (1997).